Two other TALEN edited UCART products targeting multiple myeloma (MM) antigens have also begun phase I trials—Cellectis’ UCARTCS1 product, targeting the CS1 antigen (NCT04142619) and the B-cell maturation antigen (BCMA)-targeted ALLO-715 product, licensed by Cellectis to Allogene Therapeutics (NCT04093596). This evidence concerns the gene TNFRSF17 and plasma cell myeloma.